DGAP-News
408
0 Kommentare
STADA Arzneimittel AG: Appointment of Helmut Kraft as Chief Financial Officer extended
408 
0 KommentareDGAP-News: STADA Arzneimittel AG / Key word(s): Contract
STADA Arzneimittel AG: Appointment of Helmut Kraft as Chief Financial
Officer extended
11.11.2015 / 11:52
---------------------------------------------------------------------
Bad Vilbel, November 11, 2015 - On November 11, 2015, the Supervisory Board
of STADA Arzneimittel AG extended the appointment of Helmut Kraft, Chief
Financial Officer, by one year until December 31, 2019. Kraft has been a
Member of STADA's Executive Board since 2010. His previous contract would
have ended on December 31, 2018. In addition to the area of Finance
(Controlling and Accounting, Treasury and Taxes) Kraft is also responsible
for Internal Audit, IT, Business Transformation and Investor Relations
within the Executive Board.
"I'm very pleased to have the opportunity, as a result of the extension of
the contract, to contribute to STADA's further successful development. This
includes ensuring the sustainable financial stability with which we will
further accelerate the expansion strategy of the Group", says Kraft with
regard to the perspective of the continuation of his activities on the
STADA Executive Board.
Overall, STADA's Executive Board continues to consist of Hartmut Retzlaff,
Chairman, Helmut Kraft, Chief Financial Officer, and Dr. Matthias
Wiedenfels, Chief Business Development & Central Services Officer.
Additional information for analysts:
STADA Arzneimittel AG / Investor Relations / Stadastraße 2-18 / 61118 Bad
Vilbel - Germany /
Phone: +49 (0) 6101 603-113 / Fax: +49 (0) 6101 603-215 / E-mail:
ir@stada.de
Additional information for journalists:
STADA Arzneimittel AG / Media Relations / Stadastraße 2-18 / 61118 Bad
Vilbel - Germany /
Phone: +49 (0) 6101 603-165 / Fax: +49 (0) 6101 603-215 / E-mail:
press@stada.de
Or visit us in the Internet at http://www.stada.com.
---------------------------------------------------------------------
11.11.2015 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: STADA Arzneimittel AG
Stadastraße 2-18
61118 Bad Vilbel
Germany
Phone: +49 (0)6101 603- 113
Fax: +49 (0)6101 603- 506
E-mail: communications@stada.de
Internet: www.stada.de
ISIN: DE0007251803, DE0007251845,
WKN: 725180, 725184,
Indices: MDAX
Listed: Regulated Market in Dusseldorf, Frankfurt (Prime
Standard); Regulated Unofficial Market in Berlin, Hamburg,
Hanover, Munich, Stuttgart
End of News DGAP News Service
---------------------------------------------------------------------
411717 11.11.2015
Bad Vilbel, November 11, 2015 - On November 11, 2015, the Supervisory Board
of STADA Arzneimittel AG extended the appointment of Helmut Kraft, Chief
Financial Officer, by one year until December 31, 2019. Kraft has been a
Member of STADA's Executive Board since 2010. His previous contract would
have ended on December 31, 2018. In addition to the area of Finance
(Controlling and Accounting, Treasury and Taxes) Kraft is also responsible
for Internal Audit, IT, Business Transformation and Investor Relations
within the Executive Board.
"I'm very pleased to have the opportunity, as a result of the extension of
the contract, to contribute to STADA's further successful development. This
includes ensuring the sustainable financial stability with which we will
further accelerate the expansion strategy of the Group", says Kraft with
regard to the perspective of the continuation of his activities on the
STADA Executive Board.
Overall, STADA's Executive Board continues to consist of Hartmut Retzlaff,
Chairman, Helmut Kraft, Chief Financial Officer, and Dr. Matthias
Wiedenfels, Chief Business Development & Central Services Officer.
Additional information for analysts:
STADA Arzneimittel AG / Investor Relations / Stadastraße 2-18 / 61118 Bad
Vilbel - Germany /
Phone: +49 (0) 6101 603-113 / Fax: +49 (0) 6101 603-215 / E-mail:
ir@stada.de
Additional information for journalists:
STADA Arzneimittel AG / Media Relations / Stadastraße 2-18 / 61118 Bad
Vilbel - Germany /
Phone: +49 (0) 6101 603-165 / Fax: +49 (0) 6101 603-215 / E-mail:
press@stada.de
Or visit us in the Internet at http://www.stada.com.
---------------------------------------------------------------------
11.11.2015 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: STADA Arzneimittel AG
Stadastraße 2-18
61118 Bad Vilbel
Germany
Phone: +49 (0)6101 603- 113
Fax: +49 (0)6101 603- 506
E-mail: communications@stada.de
Internet: www.stada.de
ISIN: DE0007251803, DE0007251845,
WKN: 725180, 725184,
Indices: MDAX
Listed: Regulated Market in Dusseldorf, Frankfurt (Prime
Standard); Regulated Unofficial Market in Berlin, Hamburg,
Hanover, Munich, Stuttgart
End of News DGAP News Service
---------------------------------------------------------------------
411717 11.11.2015
Diskutieren Sie über die enthaltenen Werte
Aktuelle Themen
Weitere Artikel des Autors
Verfasst von EQS Group AG
URL kopieren
Per E-Mail teilen
Artikel drucken1 im Artikel enthaltener WertIm Artikel enthaltene Werte
Auch bei Lesern beliebt
